Russell Investments Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Russell Investments Group’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-156,507	Closed	-$2.1M	–	3130
2021 Q3	$2.1M	Buy	+156,507	New	+$2.55M	﹤0.01%	1807
2021 Q2	–	Sell	-37,869	Closed	-$909K	–	3312
2021 Q1	$909K	Buy	37,869 +6,809	+22%	+$158K	﹤0.01%	2289
2020 Q4	$558K	Buy	31,060 +11,800	+61%	+$176K	﹤0.01%	2387
2020 Q3	$222K	Buy	19,260 +4,076	+27%	+$67.3K	﹤0.01%	2738
2020 Q2	$368K	Hold	15,184	–	–	﹤0.01%	2500
2020 Q1	$167K	Buy	+15,184	New	+$284K	﹤0.01%	2593
2019 Q1	–	Sell	-8,218	Closed	-$157K	–	3031
2018 Q4	$157K	Sell	8,218 -1,757	-18%	-$65.8K	﹤0.01%	2643
2018 Q3	$522K	Sell	9,975 -39,629	-80%	-$2.16M	﹤0.01%	2371
2018 Q2	$2.16M	Hold	49,604	–	–	﹤0.01%	1719
2018 Q1	$1.84M	Buy	49,604 +7,126	+17%	+$190K	﹤0.01%	1891
2017 Q4	$831K	Buy	+42,478	New	+$913K	﹤0.01%	2234

Other funds holding GTHX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Russell Investments Group's GTHX Position: Q4 2021 in Review

Russell Investments Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2021, closing a stake of 156,507 shares — an estimated $2.1M sold.

Russell Investments Group first reported a position in GTHX in Q4 2017 and held it in 11 quarters. The position peaked at $2.16M in Q2 2018. 108 funds tracked by Wall St. Rank hold GTHX as of Q4 2021.

Russell Investments Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Russell Investments Group sold 156,507 G1 Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.1M.
Russell Investments Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
Russell Investments Group's G1 Therapeutics, Inc. Common Stock position peaked at $2.16M in Q2 2018.
108 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Russell Investments Group's 13F filing for Q4 2021, filed 21 Jan 2022.